Bessemer Group
VRDN icon

Bessemer Group’s Viridian Therapeutics VRDN Stock Holding History

Bessemer Group’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7K Sell
355
-1,730
-83% -$27.9K ﹤0.01% 2226
2026
Q1 		$41K Sell
2,085
-41
-2% -$1.22K ﹤0.01% 1731
2025
Q4 		$66K Buy
2,126
+41
+2% +$1.13K ﹤0.01% 1573
2025
Q3 		$45K Buy
2,085
+1,886
+948% +$34K ﹤0.01% 1462
2025
Q2 		$3K Buy
199
+165
+485% +$2.24K ﹤0.01% 2161
2025
Q1 		$0 Sell
34
-51
-60% -$869 ﹤0.01% 2739
2024
Q4 		$2K Hold
85
– – ﹤0.01% 2281
2024
Q3 		$2K Buy
+85
New +$1.39K ﹤0.01% 2290

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Bessemer Group's VRDN Position: Q2 2026 in Review

Bessemer Group reduced its Viridian Therapeutics (VRDN) stake by 83% in Q2 2026, selling an estimated $27.9K and leaving 355 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #2226.

Bessemer Group first reported a position in VRDN in Q3 2024 and has held it in 8 quarters since. The position peaked at $66K in Q4 2025. 215 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Bessemer Group held 355 shares of Viridian Therapeutics worth $7K as of Q2 2026.
  • Bessemer Group sold 1,730 Viridian Therapeutics shares in Q2 2026, an estimated $27.9K.
  • Viridian Therapeutics made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #2226 holding.
  • Bessemer Group first reported a position in Viridian Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Bessemer Group's Viridian Therapeutics position peaked at $66K in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.